Napoleon Waszkiewicz

The Inflamed Intestinal Barrier as a Formulation Variable in Oral Nanocarrier Design: Evidence-Informed Principles for Mucus Interaction, Epithelial Access, and Translational Testing

Oral nanocarrier development for inflammatory bowel disease (IBD) is complicated by inflammation-dependent changes in mucus, epithelial integrity, and immune-cell interactions. This critical narrative review examines comparative evidence from in vitro systems, animal models, and...

PDE10A Inhibition in Schizophrenia: A Randomised, Placebo-Controlled Phase 2 Study of Alofropodect (CPL’36) in Patients Experiencing Acute Schizophrenia

BACKGROUND: Drugs that inhibit phosphodiesterase 10A (PDE10A) activity have shown efficacy in animal models. However, clinical trials of PDE10A inhibitors in patients with schizophrenia have failed to provide clinically significant results up to this point. Our study investigated...